FBLG Key Statistics, Chart & Performance
The current stock price of FBLG is 0.249 USD. In the past month the price decreased by -8.49%. In the past year, price decreased by -89.45%.
FBLG Latest News, Press Relases and Analysis
FBLG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About FBLG
Company Profile
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2024-01-31. The firm is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. The company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
Company Info
FIBROBIOLOGICS INC
455 E. Medical Center Blvd, Suite 300
Houston TEXAS US
Employees: 13
Phone: 12816715150
FIBROBIOLOGICS INC / FBLG FAQ
Can you describe the business of FIBROBIOLOGICS INC?
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2024-01-31. The firm is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. The company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
Can you provide the latest stock price for FIBROBIOLOGICS INC?
The current stock price of FBLG is 0.249 USD. The price increased by 5.55% in the last trading session.
Does FBLG stock pay dividends?
FBLG does not pay a dividend.
What is the ChartMill rating of FIBROBIOLOGICS INC stock?
FBLG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the upcoming earnings date for FIBROBIOLOGICS INC?
FIBROBIOLOGICS INC (FBLG) will report earnings on 2026-03-30.
Can you provide the short interest for FBLG stock?
The outstanding short interest for FIBROBIOLOGICS INC (FBLG) is 2.25% of its float.
FBLG Technical Analysis
FBLG Financial Highlights
Over the last trailing twelve months FBLG reported a non-GAAP Earnings per Share(EPS) of -0.48. The EPS increased by 45.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -211.59% | ||
| ROE | -14800.8% | ||
| Debt/Equity | 36.58 |